These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 31785057)
21. Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Hsieh SY; Huang SF; Yu MC; Yeh TS; Chen TC; Lin YJ; Chang CJ; Sung CM; Lee YL; Hsu CY Mol Carcinog; 2010 May; 49(5):476-87. PubMed ID: 20232364 [TBL] [Abstract][Full Text] [Related]
22. Stathmin 1 promotes the progression of liver cancer through interacting with YAP1. Liu YP; Pan LL; Kong CC Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7335-7344. PubMed ID: 32706072 [TBL] [Abstract][Full Text] [Related]
23. CTGF Mediates Tumor-Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression. Makino Y; Hikita H; Kodama T; Shigekawa M; Yamada R; Sakamori R; Eguchi H; Morii E; Yokoi H; Mukoyama M; Hiroshi S; Tatsumi T; Takehara T Cancer Res; 2018 Sep; 78(17):4902-4914. PubMed ID: 29967264 [TBL] [Abstract][Full Text] [Related]
24. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma. Steinway SN; Dang H; You H; Rountree CB; Ding W PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702 [TBL] [Abstract][Full Text] [Related]
25. Thyroid hormone suppresses expression of stathmin and associated tumor growth in hepatocellular carcinoma. Tseng YH; Huang YH; Lin TK; Wu SM; Chi HC; Tsai CY; Tsai MM; Lin YH; Chang WC; Chang YT; Chen WJ; Lin KH Sci Rep; 2016 Dec; 6():38756. PubMed ID: 27934948 [TBL] [Abstract][Full Text] [Related]
26. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications. García-Vilas JA; Medina MÁ World J Gastroenterol; 2018 Sep; 24(33):3695-3708. PubMed ID: 30197476 [TBL] [Abstract][Full Text] [Related]
27. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. Tan S; Li R; Ding K; Lobie PE; Zhu T FEBS Lett; 2011 Jul; 585(14):2229-34. PubMed ID: 21658389 [TBL] [Abstract][Full Text] [Related]
28. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042 [TBL] [Abstract][Full Text] [Related]
29. Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells. Zhong M; Zhong C; Cui W; Wang G; Zheng G; Li L; Zhang J; Ren R; Gao H; Wang T; Li X; Che J; Gohda E BMC Cancer; 2019 May; 19(1):439. PubMed ID: 31088527 [TBL] [Abstract][Full Text] [Related]
30. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046 [TBL] [Abstract][Full Text] [Related]
31. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. Huang X; Gan G; Wang X; Xu T; Xie W Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811 [TBL] [Abstract][Full Text] [Related]
32. Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling. Lau EY; Lo J; Cheng BY; Ma MK; Lee JM; Ng JK; Chai S; Lin CH; Tsang SY; Ma S; Ng IO; Lee TK Cell Rep; 2016 May; 15(6):1175-89. PubMed ID: 27134167 [TBL] [Abstract][Full Text] [Related]
33. Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma. Seitz T; Freese K; Dietrich P; Thasler WE; Bosserhoff A; Hellerbrand C Sci Rep; 2020 Mar; 10(1):4546. PubMed ID: 32161315 [TBL] [Abstract][Full Text] [Related]
34. Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma. Korhan P; Erdal E; Kandemiş E; Cokaklı M; Nart D; Yılmaz F; Can A; Atabey N PLoS One; 2014; 9(8):e105278. PubMed ID: 25148256 [TBL] [Abstract][Full Text] [Related]
35. The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling. Magistri P; Leonard SY; Tang CM; Chan JC; Lee TE; Sicklick JK J Surg Res; 2014 Apr; 187(2):377-85. PubMed ID: 24439425 [TBL] [Abstract][Full Text] [Related]
36. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity. Jo JC; Choi EK; Shin JS; Moon JH; Hong SW; Lee HR; Kim SM; Jung SA; Lee DH; Jung SH; Lee SH; Kim JE; Kim KP; Hong YS; Suh YA; Jang SJ; Choi EK; Lee JS; Jin DH; Kim TW Mol Cancer Ther; 2015 Nov; 14(11):2613-22. PubMed ID: 26351320 [TBL] [Abstract][Full Text] [Related]
37. Infiltrative Vessel Co-optive Growth Pattern Induced by IQGAP3 Overexpression Promotes Microvascular Invasion in Hepatocellular Carcinoma. Tang M; Zhang S; Yang M; Feng R; Lin J; Chen X; Xu Y; Yu R; Liao X; Li Z; Li X; Li M; Zhang Q; Chen S; Qian W; Liu Y; Song L; Li J Clin Cancer Res; 2024 May; 30(10):2206-2224. PubMed ID: 38470497 [TBL] [Abstract][Full Text] [Related]
38. C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway. Zhao M; Wang Y; Liu Y; Zhang W; Liu Y; Yang X; Cao Y; Wang S Cancer Biol Ther; 2019; 20(12):1430-1442. PubMed ID: 31441380 [TBL] [Abstract][Full Text] [Related]
39. MIRLET7BHG promotes hepatocellular carcinoma progression by activating hepatic stellate cells through exosomal SMO to trigger Hedgehog pathway. Xia Y; Zhen L; Li H; Wang S; Chen S; Wang C; Yang X Cell Death Dis; 2021 Mar; 12(4):326. PubMed ID: 33771969 [TBL] [Abstract][Full Text] [Related]
40. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways. Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]